A re-evaluation of the role of antidepressants in the treatment of bipolar depression: Data from the Stanley Foundation Bipolar Network

Bipolar Disorders

Volumn 5, Issue 6, 2003, Pages 396-406

  Post, Robert M ^a   Leverich, Gabriele S ^a   Nolen, Willem A ^b   Kupka, Ralph W ^b   Altshuler, Lori L ^c   Frye, Mark A ^c   Suppes, Trisha ^d   McElroy, Susan ^e   Keck Jr , Paul ^e   Grunze, Heinze ^f   Walden, Jorg ^g  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF TEXAS AT DALLAS   (United States)

^e UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^f UNIVERSITY OF MUNICH   (Germany)

^g TU BERGAKADEMIE FREIBERG   (Germany)

Author keywords

Adjuncts; Antidepressants; Bipolar depression; Bupropion; Morbidity; Outcome; Relapse; Sertraline; Switching; Venlafaxine

Indexed keywords

AMFEBUTAMONE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; CARBAMAZEPINE; DESIPRAMINE; FLUOXETINE; GABAPENTIN; ICOSAPENTAENOIC ACID; IMIPRAMINE; LAMOTRIGINE; LITHIUM; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; NORADRENALIN UPTAKE INHIBITOR; OMEGA 3 FATTY ACID; OXCARBAZEPINE; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; THYROID HORMONE; THYROXINE; TRANYLCYPROMINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROIC ACID; VENLAFAXINE;

ADULT; BIPOLAR DEPRESSION; BIPOLAR DISORDER; CLINICAL TRIAL; DISEASE SEVERITY; DRUG ERUPTION; DRUG MECHANISM; DRUG PREFERENCE; DRUG RESPONSE; DRUG USE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; HYPOMANIA; MALE; MANIA; MENTAL HEALTH; MORBIDITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENCE RISK; RETROSPECTIVE STUDY; REVIEW; RISK BENEFIT ANALYSIS;

ADULT; AFFECT; ANTIDEPRESSIVE AGENTS; BIPOLAR DISORDER; DEPRESSIVE DISORDER; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOUNDATIONS; HUMANS; MALE; MONOAMINE OXIDASE INHIBITORS; MORBIDITY; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS; RECURRENCE; RETROSPECTIVE STUDIES; TIME FACTORS; TRIAZINES; VALPROIC ACID;

EID: 0346025646     PISSN: 13985647     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1399-5618.2003.00065.x     Document Type: Review

References (64)

1. Altshuler LL, Post RM, Leverich GS, Mikalauskas K, Rosoff A, Ackerman L. Antidepressant-induced mania and cycle acceleration: a controversy revisited. Am J Psychiatry 1995; 152: 1130-1138.
2. Post RM, Denicoff KD, Leverich GS, Frye MA. Drug-induced switching in bipolar disorder. Epidemiology and therapeutic implications. CNS Drugs 1997; 8: 352-365.
3. Leverich GS, Nolen WA, Rush AJ et al. The Stanley Foundation Bipolar Treatment Outcome Network. I. Longitudinal methodology. J Affect Disord 2001; 67: 33-44.
4. Post RM, Altshuler LL, Frye MA et al. Rate of switch in bipolar patients prospectively treated with second-generation antidepressants as augmentation to mood stabilizers. Bipolar Disord 2001; 3: 259-265.
5. Altshuler L, Kiriakos L, Calcagno J et al. The impact of antidepressant discontinuation versus antidepressant continuation on 1-year risk for relapse of bipolar depression: a retrospective chart review. J Clin Psychiatry 2001; 62: 612-616.
6. Altshuler L, Suppes T, Black D et al. Impact of antidepressant discontinuation after acute remission from bipolar depression on rates of depressive relapse at one-year follow-up. Am J Psychiatry 2003; 160: 1252-1262.
7. Post RM, Denicoff KD, Leverich GS et al. Morbidity in 258 bipolar outpatients followed for one year with daily prospective ratings on the NIMH-Life Chart Method. J Clin Psychiatry 2003; 64: 680-690.
8. Post RM, Altshuler LL, Suppes P, Denicoff KD, Kupka R, Nolen WA. The treatment of bipolar depression. Syllabus and Proceedings Summary of the Annual Meeting of the American Psychiatric Association, May 5-10, 2001: 92.
9. Rush AJ, Giles DE, Schlesser MA, Fulton CL, Weissenburger J, Burns CA. The inventory for depressive symptomatology (IDS): Preliminary findings. Psychiatr Res 1986; 18: 65-87.
10. Rush AJ, Gullion CM, Basco MR, Jarrett RB, Trivedi MH. The Inventory of Depressive Symptomatology (IDS): psychometric properties. Psychol Med 1996; 26: 477-486.
11. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978; 133: 429-435.
12. Leverich GS, Post RM. Life charting the course of bipolar disorder. Current review of mood and anxiety disorders 1996; 1: 48-61.
13. Leverich GS, Post RM. Life charting of affective disorders. CNS Spectrums 1998; 3: 21-37.
14. Goodwin FK, Jamison KR. Manic-Depressive Illness. New York: Oxford University Press, 1990.
15. Leverich GS, McElroy SL, Suppes T et al. Early physical and sexual abuse associated with an adverse course of bipolar illness. Biol Psychiatry 2002; 51: 288-297.
16. Spearing MK, Post RM, Leverich GS, Brandt D, Nolen W. Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res 1997; 73: 159-171.
17. Post RM, Weiss SRB. Neurobiological models of recurrence in mood disorder. In: Charney DS, Nestler EJ, Bunney BS eds. Neurobiology of Mental Illness. New York, NY: Oxford University Press, 1999: 365-384.
18. Fava M, Schmidt ME, Zhang S, Gonzales J, Raute NJ, Judge R. Treatment approaches to major depressive disorder relapse. Part 2: Reinitiation of antidepressant treatment. Psychother Psychosom 2002; 71: 195-199.
19. Schmidt ME, Fava M, Zhang S, Gonzales J, Raute NJ, Judge R. Treatment approaches to major depressive disorder relapse. Part 1: Dose increase. Psychother Psychosom 2002; 71: 190-194.
20. Sharma V. Loss of response to antidepressants and subsequent refractoriness: diagnostic issues in a retrospective case series. J Affect Disord 2001; 64: 99-106.
21. Egeland JA, Blumenthal RL, Nee J, Sharpe L, Endicott J. Reliability and relationship of various ages of onset criteria for major affective disorder. J Affect Disord 1987; 12: 159-165.
22. Lish JD, Dime-Meenan S, Whybrow PC, Price RA, Hirschfeld RM. The National Depressive and Manic-depressive Association (DMDA) survey of bipolar members. J Affect Disord 1994; 31: 281-294.
23. Denicoff KD, Smith-Jackson EE, Disney ER, Ali SO, Leverich GS, Post RM. Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder. J Clin Psychiatry 1997; 58: 470-478.
24. O'Connell RA, Mayo JA, Flatow L, Cuthbertson B, O'Brien BE. Outcome of bipolar disorder on long-term treatment with lithium. Br J Psychiatry 1991; 159: 123-129.
25. Gelenberg AJ, Kane JM, Keller MB et al. Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorder. N Engl J Med 1989; 321: 1489-1493.
26. Goldberg JF, Harrow M, Leon AC. Lithium treatment of bipolar affective disorders under naturalistic followup conditions. Psychopharmacol Bull 1996; 32: 47-54.
27. Maj M, Pirozzi R, Magliano L, Bartoli L. Long-term outcome of lithium prophylaxis in bipolar disorder: A 5-year prospective study of 402 patients at a lithium clinic. Am J Psychiatry 1998; 155: 30-35.
28. Gitlin MJ, Swendsen J, Heller TL, Hammen C. Relapse and impairment in bipolar disorder. Am J Psychiatry 1995; 152: 1635-1640.
29. Vestergaard P. Treatment and prevention of mania: a Scandinavian perspective. Neuropsychopharmacology 1992; 7: 249-259.
30. Moncrieff J. Lithium revisited: a re-examination of the placebo-controlled trials of lithium prophylaxis in manic-depressive disorder. Br J Psychiatry 1995; 167: 569-574.
31. Sachs GS, Lafer B, Stoll AL et al. A double-blind trial of bupropion versus desipramine for bipolar depression. J Clin Psychiatry 1994; 55: 391-393.
32. Guille C, Shriver A, Demopulos C, Sachs G. Bupropion vs. desipramine in the treatment of bipolar depression. Bipolar Disord 1999; 1(Suppl 1): 33.
33. Young LT, Joffe RT, Robb JC, MacQueen GM, Marriott M, Patelis-Siotis I. Double-blind comparison of addition of a second mood stabilizer versus an antidepressant to an initial mood stabilizer for treatment of patients with bipolar depression. Am J Psychiatry 2000; 157: 124-126.
34. Nemeroff CB, Evans DL, Gyulai L et al. Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry 2001; 158: 906-912.
35. Calabrese JR, Bowden CL, Sachs GS, Ascher JA, Monaghan E, Rudd GD. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry 1999; 60: 79-88.
36. Bowden CL, Calabrese JR, Sachs GS et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003; 60: 392-400.
37. Calabrese JR, Bowden CL, Sachs G et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 2003; 64: 1013-1024.
38. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002; 159: 1-50.
39. Post RM, Speer AM, Leverich GS. Bipolar illness: What critical treatment issues need studying? Clin Approaches Bipolar Disord 2003; 2: 24-30.
40. Muller-Oerlinghausen B, Ahrens B, Grof E et al. The effect of long-term lithium treatment on the mortality of patients with manic-depressive and schizoaffective illness. Acta Psychiatr Scand 1992; 86: 218-222.
41. Muller-Oerlinghausen B, Muser-Causemann B, Volk J. Suicides and parasuicides in a high-risk patient group on and off lithium long-term medication. J Affect Disord 1992; 25: 261-269.
42. Ahrens B, Muller-Oerlinghausen B, Schou M et al. Excess cardiovascular and suicide mortality of affective disorders may be reduced by lithium prophylaxis. J Affect Disord 1995; 33: 67-75.
43. Sachs GS, Thase ME, Otto MW et al. Rationale, design, and methods of the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Biol Psychiatry 2003; 53: 1028-1042.
44. Thase ME, Mallinger AG, McKnight D, Himmelhoch JM. Treatment of imipramine-resistant recurrent depression, IV: A double-blind crossover study of tranylcypromine for anergic bipolar depression. Am J Psychiatry 1992; 149: 195-198.
45. Cohn JB, Collins G, Ashbrook E, Wernicke JF. A comparison of fluoxetine, imipramine and placebo in patients with bipolar depressive disorder. Int Clin Psychopharmacol 1989; 4: 313-322.
46. Himmelhoch JM, Thase ME, Mallinger AG, Houck P. Tranylcypromine versus imipramine in anergic bipolar depression. Am J Psychiatry 1991; 148: 910-916.
47. Haykal RF, Akiskal HS. Bupropion as a promising approach to rapid cycling bipolar II patients. J Clin Psychiatry 1990; 51: 450-455.
48. Bauer M, Bschor T, Kunz D, Berghofer A, Strohle A, Muller-Oerlinghausen B. Double-blind, placebo-controlled trial of the use of lithium to augment antidepressant medication in continuation treatment of unipolar major depression. Am J Psychiatry 2000; 157: 1429-1435.
49. Bauer M, Dopfmer S. Lithium augmentation in treatment-resistant depression: Meta-analysis of placebo-controlled studies. J Clin Psychopharmacol 1999; 19: 427-434.
50. Joffe RT, Singer W. A comparison of triiodothyronine and thyroxine in the potentiation of tricyclic antidepressants. Psychiatry Res 1990; 32: 241-251.
51. Goodwin FK, Prange AJ, Post RM, Muscettola G, Lipton MA. Potentiation of antidepressant effects by L-triiodothyronine in tricyclic nonresponders. Am J Psychiatry 1982; 139: 34-38.
52. Joffe RT. The use of thyroid supplements to augment antidepressant medication. J Clin Psychiatry 1998; 59 (Suppl 5): 26-29.
53. Aronson R, Offman HJ, Joffe RT, Naylor CD. Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis. Arch Gen Psychiatry 1996; 53: 842-848.
54. Coppen A, Chaudhry S, Swade C. Folic acid enhances lithium prophylaxis. J Affective Discord 1986; 10: 9-13.
55. Coppen A, Bailey J. Enhancement of the antidepressant action of fluoxetine by folic acid: A randomised, placebo controlled trial. J Affect Disord 2000; 60: 121-130.
56. Stoll AL, Severus WE, Freeman MP et al. Omega 3 fatty acids in bipolar disorder: A preliminary double-blind, placebo-controlled trial. Arch Gen Psychiatry 1999; 56: 407-412.
57. Peet M, Horrobin DF. A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch Gen Psychiatry 2002; 59: 913-919.
58. Nemets B, Stahl Z, Belmaker RH. Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. Am J Psychiatry 2002; 159: 477-479.
59. Bauer MS, Whybrow PC. Rapid cycling bipolar affective disorder. II Treatment of refractory rapid cycling with high-dose levothyroxine: A preliminary study. Arch Gen Psychiatry 1990; 47: 435-440.
60. Bauer M, Priebe S, Berghofer A, Bschor T, Kiesslinger U, Whybrow PC. Subjective response to and tolerability of long-term supraphysiological doses of levothyroxine in refractory mood disorders. J Affect Disord 2001; 64: 35-42.
61. Bauer M, London ED, Rasgon N et al. Effects of supraphysiological doses of L-thyroxine on regional cerebral glucose metabolism in bipolar disorder. ACNP Abstracts 2001; 362.
62. Bauer M, Baur H, Berghofer A et al. Effects of supraphysiological thyroxine administration in healthy controls and patients with depressive disorders. J Affect Disord 2002; 68: 285-294.
63. Post RM, Frye MA, Denicoff KD, Speer AM, Weiss SRB, Leverich GS. Preliminary algorithms for treatment-resistant bipolar depression. In: Amsterdam J, Hornig-Rohan M, Nierenberg AA eds. Refractory Mood Disorders. Cambridge: Cambridge University Press, 2001: 350-404.
64. Judd LL, Paulus MJ, Schettler PJ et al. Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness? Am J Psychiatry 2000; 157: 1501-1504.